Primary progressive multiple sclerosis

Neurological Sciences

Volumn 22, Issue SUPPL. 2, 2001, Pages

  Montalban, X ^a   Rio, J ^a  

^a Vail d'Hebron University Hospital   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; BETA INTERFERON; CELL ADHESION MOLECULE; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; GLATIRAMER; HLA ANTIGEN; IMMUNOGLOBULIN G; INTERFERON BETA SERINE; METHOTREXATE; MITOXANTRONE; MYELIN BASIC PROTEIN; PLACEBO; PROTEOLIPID PROTEIN; SALAZOSULFAPYRIDINE; BETA1A INTERFERON; CYANOCOBALAMIN; IMMUNOGLOBULIN; MITOCHONDRIAL DNA; VERY LONG CHAIN FATTY ACID;

ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE COURSE; EVOKED VISUAL RESPONSE; GENETIC ASSOCIATION; HAPLOTYPE; HUMAN; IMMUNOGLOBULIN PRODUCTION; LYMPH NODE IRRADIATION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PATHOLOGY; PATIENT SELECTION; PROGNOSIS; RELAPSE; ADRENOLEUKODYSTROPHY; ANTERIOR HORN CELL DISEASE; BORRELIA; BRAIN INJURY; BRUCELLA; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM INFECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DIFFERENTIAL DIAGNOSIS; ELECTROMYOGRAM; ERYTHROCYTE SEDIMENTATION RATE; HEREDITARY OPTIC ATROPHY; HUMAN T CELL LEUKEMIA VIRUS 1; SARCOIDOSIS; SPASTIC PARAPLEGIA; SPINAL ANGIOGRAPHY; SPINAL CORD COMPRESSION; SPINAL CORD INJURY; SYPHILIS; SYSTEMIC DISEASE; THORAX RADIOGRAPHY;

HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; INTERFERONS; MITOXANTRONE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; PEPTIDES; PROGNOSIS;

EID: 0036174676     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100720100032     Document Type: Article

References (74)

1. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46:907-911
2. Filippi M, Campi A, Martinelli V, Pereira C, Scotti G, Comi G (1995) Transitional progressive multiple sclerosis: MRI and MTI findings. Acta Neurol Scand 92:178-182
3. Kremenchutzky M, Cottrell D, Rice G et al (1999) The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: are-evaluation. Brain 122:1941-1949
4. Bonduelle M, Albaranes R (1962) Etude statistique de 145 cases de la sclérose en plaque. Sem Hop Paris 38:3762-3773
5. Minderhoud JM, van der Hoeven JH, Prange AJ ( 1988) Course and prognosis of chronic progressive multiple sclerosis. Results of an epidemiological study. Acta Neurol Scand 78:10-15
6. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carrière W, Baskerville J et al (1989) The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain 112:133-146
7. Thompson AJ, Polman CH, Miller DH, McDonald WI, Brochet B, Filippi M et al (1997) Primary progressive multiple sclerosis. Brain 120:1085-1096
8. Confavreux C, Aimard G, Dévie M (1980) Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 103:281-300
9. Poser CM, Paty PW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-231
10. Runmarker B, Andersen O (1993) Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 116:117-134
11. Cottrell DA, Kremenchutzky M, Rice GPA, Koopman WJ, Hader W, Baskerville J et al (1999) The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 122:625-639
12. Confavreux C, Vukosic S, Moreau T, Adeline P (2000) Relapses and progression of disability in multiple sclerosis. N Engl JMed 343:1430-143 8
13. Stevenson VL, Miller DH, Leary SM, Rovaris M, Barkhof F, Brochet B et al (2000) One year follow up study of primary and transitional progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 68:713-718
14. Jersild C, Svejgaard A, Fog T (1972) HL-A antigens in multiple sclerosis. Lancet 1:1240-1241
15. Madigand M, Oger JJ-F, Fauchert R, Sabouraud O, Genetet B (1982) HL profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypes. J Neurol Sei 53:519-522
16. Van Lambalgen R, Sanders EACM, D'Amaro J (1986) Sex distribution, age of onset and HLA profiles in two types of multiple sclerosis. J Neurol Sei 76:13-21
17. Francis DA, Batchelor JR. McDonald WI, Hing SN, Dodi IA, Fielder AH et al (1987) Multiple sclerosis in north-east Scotland: an association with HLA DQwl. Brain 110:181-196
18. Olerup O, Hillert J, Fredrikson S, Olsson T, Kam-Hansen S, Moller E et al (1989) Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc Natl Acad Sei USA 86:7113-7117
19. Hillert J, Grönning M, Nyland H, Link H, Olerup O ( 1992) An immunogenetic heterogeneity in multiple sclerosis. J Neurol Neurosurg Psychiatry 55:887-890
20. Weinshenker BG, Santrach P, Schaid D, Rodriguez M (1995) Association between class II major histocompatibility complex polymorphims and the course of multiple sclerosis Neurology 45[Suppl 4]:A384 (abstract)
21. Magalhàes A, de Sa J (1993) CSF profiles in primary progressive and relapsing/remitting forms of multiple sclerosis. In: ECTRIMS 93. Congress Book of Abstracts, p 74
22. Pirttilä T, Nurmikko T (1995) CSF oligoclonal bands, MRI, and the diagnosis of multiple sclerosis. Acta Neurol Scand 92:468-471
23. Warren KG, Catz I (1994) Relative frequency of autoantibodies to myelin basic protein in optic neuritis and multiple sclerosis cerebrospinal fluid. J Neurol Sei 121:66-73
24. Acarin N, Rio J, Fernândez AL, Tintoré M, Durän I, Galân I et al (1996) Different antiganglioside antibodies pattern between relapsing-remitting and progressive multiple sclerosis. Acta Neurol Scand 93:99-103
25. Sadatipour BT, Greer JM, Pender MP ( 1998) Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol 44:980-983
26. Sharief MK, Hentges R (1991) Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 325:467-472
27. Peter JB, Boctor FN, Tourtellotte WW ( 1991 ) Serum and CSF levels of IL-2, sIL-2R, TNF-ct, and IL-1 in chronic progressive multiple sclerosis: expected lack of clinical utility. Neurology 41:121-123
28. Durân I, Martinez-Câceres EM, Brieva L, Tintoré M, Montalban X (2001) Similar pro- and anti-inflammatory cytokine production in the different clinical forms of multiple sclerosis. Mult Scler 7:151-156
29. Prat A, Pelletier D, Duquette P, Arnold DL, Antel JP (2000) Heterogeneity of T-lymphocyte function in primary progressive multiple sclerosis: relation to magnetic resonance imaging lesion volume. Ann Neurol 47:234-237
30. Dore-Duffy P, Newman W, Balabanov R, Lisak RP, Mainolfi E, Rothlein R et al (1995) Circulating, soluble adhesion proteins in cerebrospinal fluid and serum of patients with multiple sclerosis: correlation with clinical activity. Ann Neurol 37:55-62
31. Härtung HP, Reiners K, Archelos JJ, Michels M, Seeldrayers P, Heidenreich F et al (1995) Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann Neurol 38:186-193
32. Matsuda M, Tsukada N, Miyagi K, Yanagisawa N (1995) Increased levels of soluble vascular cell adhesion molecule-1 (VCAM-1) in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T lymphotropic virus type-1 associated myelopathy. J Neuroimmunol 59:35-0
33. Giovannoni G, Lai M, Thorpe J, Kidd D, Chamoun V, Thompson AJ et al (1997) Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging. Neurology 48:1557-1565
34. Giovannoni G, Thorpe JW, Kidd D, Kendall BE, Moseley IF, Thompson AJ et al ( 1996) Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease. J Neurol Neurosurg Psychiatry 60:20-26
35. McDonnell GV, McMillan SA, Douglas JP, Droogan AG, Hawkins SA (1999) Serum soluble adhesion molecules in multiple sclerosis: raised sVCAM-1, sICAM-1 and sEselectin in primary progressive disease. J Neurol 246:87-92
36. Durân I, Martinez-Câceres EM, Rio J, Barbera N, Marzo ME, Montalban X (1999) Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules. Brain 122:2297-2307
37. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI (1994) A comparison of the pathology of primary and secondary multiple sclerosis. Brain 117:759-765
38. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity if multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol47:707-717
39. Thompson AJ, Kermode AG, MacManus DG, Kendall BE, Kingsley DPE, Moseley IF et al (1990) Patterns of disease activity in multiple sclerosis: a clinical and magnetic resonance imaging study. BMJ 300:631-634 (Comment in: BMJ 300:1272)
40. Thompson AJ, Kermode AG, MacManus DG, Kingsley DPE, Kendall BE, Moseley IF et al (1989) Pathogenesis of primary progressive multiple sclerosis. Lancet 1:1322-1323
41. 4L Kappos L, Stadt D, Rohrbach E, Weil W (1998) Gadolinium-DTPA-enhanced magnetic resonance imaging in the evaluation of different disease courses and disease activity in MS. Neurology 38:255 (abstract)
42. Thompson AJ, Kermode AG, Wicks D, MacManus DG, Kendall BE, Kingsley DP et al ( 1991 ) Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 29:53-62
43. Kidd DK, Thorpe JW, Thompson AJ, Kendall BE, Moseley IF, MacManus DG et al (1993) Spinal cord MRI using multiarray coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 43:2632-2637
44. Kidd DK, Thorpe JW, Kendall BE, Barker GJ, Miller DH, McDonald WI et al (1996) MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 60:15-19
45. Losseff NA, Webb SL, O'Riordan JI, Page R, Wang L, Barker GJ et al (1996) Spinal cord atrophy and disability in multiple sclerosis: a new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 119:701-708
46. Lycklama a Nijeholt GJ, Barkhof F, Scheltens P, Castelijns JA, Adèr H, van Waesberghe JH et al (1997) MR of the spinal cord in multiple sclerosis: relation to clinical subtype and disability. AJNR Am J Neuroradiol 18:1041-1048
47. Davie CA, Barker GJ, Webb S, Tofts PS, Thompson AJ, Miller DH et al (1996) A proton spectroscopy study of disability in multiple sclerosis. J Neurol 243[Suppl 2]:S33 (abstract)
48. Cucurella MG, Rovira A, Rio J, Pedraza S, Tintoré M, Montalban X et al (2000) Proton magnetic resonance spectroscopy in primary and secondary progressive multiple sclerosis. NMR Biomed 13:57-63
49. Gass A, Barker GJ, Kidd D, Thorpe JW, MacManus D, Brennan A et al (1994) Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol 36:62-67
50. Dousset V, Grossman RI, Ramer KN, Schnall MD, Young LH, Gonzalez-Scarano F et al (1992) Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology 182:483-91
51. Filippi M, Campi A, Dousset V, Baratti C, Martinelli V, Canal N et al ( 1995) A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology 45:478-482
52. Thompson AJ, Montalban X, Barkhof F, Brochet B, Filippi M, Miller DH et al (2000) Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 47:831-835
53. McDonald WI, Compston A, Edan G, Goodkin D, Härtung HP, Lublin FD et al (2001) Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121-127
54. Leary SM, Stevenson VL, Miller DH, Thompson AJ ( 1999) Problems in designing and recruiting to therapeutic trials in primary progressive multiple sclerosis. J Neurol 246:562-568
55. Brieva L, Pericot I, Rovira A, Galân I, Nos C, Montalban X. Validation of primary progressive multiple sclerosis criteria in a sample of patients included in a phase II placebo controlled trial. 16th Congress of the European Committee for Treatment and Research Multiple Sclerosis. Toulouse, France. 6-9 September 2000. Rev Neurol (Paris) 156[Suppl 3]:3S35
56. Pericot I, Brieva L, Marzo ME, Borrâs C, Villoslada P, Montalban X (2000) Primary and transitional multiple sclerosis follow-up. Changes in clinical forms. 16th Congress of the European Committee for Treatment and Research Multiple Sclerosis. Toulouse, France. 6-9 September 2000. Rev Neurol (Paris) 156[Suppl 3]:3S23
57. Yudkin PL, Ellison GW, Ghezzi A et al (1991) Overview of azathioprine treatment in multiple sclerosis. Lancet 338:1051-1055
58. Hauser SL, Dawson DM, Lehrich JR et al (1983) Intensive immunosuppression in progressive multiple sclerosis; a randomized, three arm study of high dose intravenous cyclophosphamide, plasma exchange and ACTH. N Engl J Med 308:183-188
59. The Canadian Cooperative Multiple Sclerosis Study Group (1991) The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 337:441-446
60. Likosky WH, Fireman B, Elmore R et al (1991) Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry 54:1055-1060
61. The Multiple Sclerosis Study Group (1990) Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomised double-blinded, placebo-controlled clinical trial. Ann Neurol 27:591-605
62. Currier RD, Haerer AF, Meydrech EF (1993) Low dose oral methotrexate treatment of multiple sclerosis: a pilot study. J Neurol Neurosurg Psychiatry 56:1217-1218
63. Cook SD, Devereux C, Troiano R et al (1986) Effect of total lymphoid irradiation in chronic progressive MS. Lancet 1:1405-1409
64. Noseworthy JH, Hopkins MB, Vandervoort MK et al (1993) An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 43:1401-1406
65. Edan G, Miller DH, Clanet M et al ( 1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62:112-118
66. Rice GPA and the Cladribine Study Group (2000) Cladribine and progressive multiple sclerosis: Clinical and MRI outcomes of a multicenter controlled trial. Neurology 54:1145-1155
67. Millefiorini E, Gasperini C, Pozzilli C et al (1997) Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 244:153-159
68. Bornstein MB, Miler A, Slagle S ( 1991 ) A placebo-controlled, double blind randomized, two center pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 41:533-539
69. IFNB Multiple Sclerosis Study Group (1993) Interferon betaIb is effective in relapsing-remitting multiple sclerosis. Neurology 43:655-661
70. Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285-294
71. - (1998) PRIMS Study Group. Randomised, double-blind, placebo-controlled study of interferon beta-la in relapsingremitting multiple sclerosis. Lancet 352:1498-1504
72. - (1998) European Study Group on Interferon Beta-lb in Secondary Progressive Multiple Sclerosis. Placebo-controlled multicentre randomised trial of interferon beta-lb in treatment of secondary progressive multiple sclerosis. Lance, 352:1491-1497
73. - (2001) Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1 a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1 a in secondary progressive MS: Clinical results. Neurology 56:1496-504
74. Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H (2000) The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. J Neuroimmunol 107:161-166